Our research group studies biomarkers for aggressive prostate cancer.
Markers are needed to detect aggressive and potential lethal prostate cancer at an early, curable stage. In addition, knowledge is needed about why certain tumors become aggressive so that new treatments can be developed.
We use proteomics, metabolomics and genomics methods to study blood and tissue in search of tumor markers for prostate cancer. We also use experimental model systems to functionally evaluate novel therapeutic targets. We want to develop sensitive methods to detect tumors and predict how harmful they are at an early stage of the disease, so that patients can receive optimal treatment at a curable stage. In addition, these markers can hopefully help us develop new treatments for prostate cancer.